Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer Journal Article
| Authors: | Markman, M.; Hakes, T.; Reichman, B.; Curtin, J.; Barakat, R.; Rubin, S.; Jones, W.; Lewis, J. L. Jr; Almadrones, L.; Hoskins, W. |
| Article Title: | Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer |
| Abstract: | Eighteen previously treated patients with advanced ovarian cancer were entered into a phase 2 trial of chronic low-dose oral etoposide (50 mg/day for 20 days, repeated every 28 days) to determine the activity of this therapeutic strategy in organoplatinum-refractory disease. The treatment program was generally well tolerated, with mild neutropenia the most common side-effect encountered. One patient (6%; 95% confidence interval=0-17%) achieved a partial response, which lasted for 11 months. Three additional patients (17%), who failed to meet the criteria of a partial response, demonstrated objective evidence of antineoplastic activity. Chronic low-dose oral etoposide administration is associated with definite, although modest, activity in platinumrefractory ovarian cancer. © 1992 Springer-Verlag. |
| Keywords: | adult; clinical article; aged; neutropenia; cisplatin; ovarian cancer; ovarian neoplasms; carboplatin; ovary cancer; phase 2 clinical trial; etoposide; drug administration schedule; drug resistance; therapy; human; female; article; cancer chemo |
| Journal Title: | Journal of Cancer Research and Clinical Oncology |
| Volume: | 119 |
| Issue: | 1 |
| ISSN: | 0171-5216 |
| Publisher: | Springer |
| Date Published: | 1992-01-01 |
| Start Page: | 55 |
| End Page: | 57 |
| Language: | English |
| DOI: | 10.1007/bf01209489 |
| PUBMED: | 1400568 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
